Posted by Michael Wonder on 26 Nov 2023
‘Verzenio, a ray of hope for breast cancer patients, should get insurance benefits’
24 November 2023 - A petition has been posted to call for providing insurance benefits for Lilly's CDK 4/6 inhibitor Verzenio (abemaciclib) for early stage breast cancer.
Last year, the Ministry of Food and Drug Safety approved Verzenio combined with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor positive, HER2 negative, lymph node positive, high risk recurrent early breast cancer.
Lilly immediately set about to expand reimbursement for Verzenio.
